Related Experiment Videos
Postmarketing surveillance: practical experience with ketotifen.
British Medical Journal (Clinical Research Ed.)
|March 24, 1984
Summary
Postmarketing surveillance of ketotifen (Zaditen) for asthma prophylaxis found it effective in 70% of patients. This study confirmed known efficacy and safety, similar to clinical trials, with no unexpected side effects.
Area of Science:
- Pharmacology
- Clinical Pharmacy
- Respiratory Medicine
Background:
- Ketotifen (Zaditen) is an oral medication used for preventing bronchial asthma attacks.
- Postmarketing surveillance is crucial for evaluating real-world drug performance and safety.
Purpose of the Study:
- To assess the adverse events and efficacy of ketotifen in a large patient cohort.
- To evaluate the collaborative process between industry, regulatory bodies, and healthcare providers.
Main Methods:
- A one-year postmarketing surveillance study involving 8291 patients with asthma.
- Regular data collection every three months to record adverse events and subjective efficacy.
Main Results:
- Subjective assessment indicated that 70% of patients found ketotifen efficacious.
- Adverse events were consistent with those reported in prior clinical trials, with no unexpected or unacceptable findings.
- The study demonstrated successful collaboration among pharmaceutical industry, regulatory authorities, and prescribing physicians.
Conclusions:
- Ketotifen demonstrates significant efficacy and a favorable safety profile in a broad asthma patient population.
- The value of large-scale postmarketing surveys in confirming known drug characteristics requires further evaluation.
- Real-world data collection supports ongoing efforts in medication safety and prescribing practices.